The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer

• Published in: Seminars in cancer biology Vol. 29; pp. 3 - 12
• Main Authors: Lederer, Marcell, Bley, Nadine, Schleifer, Christian, Hüttelmaier, Stefan
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.12.2014
• Subjects: Antigens, Neoplasm - genetics; Cell Proliferation; Cell Transformation, Neoplastic - genetics; CRD-BP; Drug Resistance, Neoplasm - genetics; Gene Expression Regulation, Neoplastic; Hematology, Oncology and Palliative Medicine; Humans; IGF2 mRNA-binding protein; IGF2BP; IMP; Neoplasm Metastasis - genetics; Neoplasm Metastasis - pathology; Neoplasms - genetics; Neoplasms - pathology; RNA-Binding Proteins - biosynthesis; RNA-Binding Proteins - genetics; VICKZ; VICKZ; CRD-BP; IGF2BP; IGF2 mRNA-binding protein; IMP
• ISSN: 1044-579X; 1096-3650; 1096-3650
• DOI: 10.1016/j.semcancer.2014.07.006

The post-transcriptional control of gene expression mediated by RNA-binding proteins (RBPs), long non-coding RNAs (lncRNAs) as well as miRNAs is essential to determine tumor cell fate and thus is a major determinant in cancerogenesis. The IGF2 mRNA binding protein family (IGF2BPs) comprises three RBPs. Two members of the family, IGF2BP1 and IGF2BP3, are bona fide oncofetal proteins, which are de novo synthesized in various human cancers. In vitro studies revealed that IGF2BPs serve as post-transcriptional fine-tuners modulating the expression of genes implicated in the control of tumor cell proliferation, survival, chemo-resistance and metastasis. Consistently, the expression of both IGF2BP family members was reported to correlate with an overall poor prognosis and metastasis in various human cancers. Due to the fact that most reports used a pan-IGF2BP antibody for studying IGF2BP expression in cancer, paralogue-specific functions can barely be evaluated at present. Nonetheless, the accordance of IGF2BPs’ role in promoting an aggressive phenotype of tumor-derived cells in vitro and their upregulated expression in aggressive malignancies provides strong evidence that IGF2BPs are powerful post-transcriptional oncogenes enhancing tumor growth, drug-resistance and metastasis. This suggests IGF2BPs as powerful biomarkers and candidate targets for cancer therapy.